Free Trial
NASDAQ:MDXG

MiMedx Group (MDXG) Stock Price, News & Analysis

MiMedx Group logo
$5.94 0.00 (0.00%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$5.92 -0.02 (-0.34%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MiMedx Group Stock (NASDAQ:MDXG)

Key Stats

Today's Range
$5.86
$6.02
50-Day Range
$5.81
$7.43
52-Week Range
$5.47
$10.14
Volume
1.99 million shs
Average Volume
670,621 shs
Market Capitalization
$877.34 million
P/E Ratio
22.00
Dividend Yield
N/A
Price Target
$12.50
Consensus Rating
Buy

Company Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

MiMedx Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

MDXG MarketRank™: 

MiMedx Group scored higher than 76% of companies evaluated by MarketBeat, and ranked 274th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MiMedx Group has received no research coverage in the past 90 days.

  • Read more about MiMedx Group's stock forecast and price target.
  • Earnings Growth

    Earnings for MiMedx Group are expected to grow by 6.67% in the coming year, from $0.30 to $0.32 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MiMedx Group is 22.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.93.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MiMedx Group is 22.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.27.

  • Price to Book Value per Share Ratio

    MiMedx Group has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about MiMedx Group's valuation and earnings.
  • Percentage of Shares Shorted

    3.44% of the float of MiMedx Group has been sold short.
  • Short Interest Ratio / Days to Cover

    MiMedx Group has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in MiMedx Group has recently decreased by 3.66%, indicating that investor sentiment is improving.
  • Dividend Yield

    MiMedx Group does not currently pay a dividend.

  • Dividend Growth

    MiMedx Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.44% of the float of MiMedx Group has been sold short.
  • Short Interest Ratio / Days to Cover

    MiMedx Group has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in MiMedx Group has recently decreased by 3.66%, indicating that investor sentiment is improving.
  • News Sentiment

    MiMedx Group has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for MiMedx Group this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for MDXG on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MiMedx Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,268,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.70% of the stock of MiMedx Group is held by insiders.

  • Percentage Held by Institutions

    79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MiMedx Group's insider trading history.
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MDXG Stock News Headlines

MDXG MiMedx Group, Inc. - Seeking Alpha
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Director Of MiMedx Group Makes $185K Buy
MIMEDX to Participate in Upcoming Investor Conferences
Zooming In On MiMedx Group's Earnings
See More Headlines

MDXG Stock Analysis - Frequently Asked Questions

MiMedx Group's stock was trading at $9.62 at the beginning of the year. Since then, MDXG stock has decreased by 38.3% and is now trading at $5.94.
View the best growth stocks for 2025 here
.

MiMedx Group, Inc (NASDAQ:MDXG) issued its earnings results on Wednesday, April, 30th. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The firm earned $88.21 million during the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 11.40% and a trailing twelve-month return on equity of 22.70%.
Read the conference call transcript
.

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MiMedx Group investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Hawkins (HWKN), Adobe (ADBE) and GE Aerospace (GE).

Company Calendar

Last Earnings
4/30/2025
Today
6/30/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:MDXG
Employees
870
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$13.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+110.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
22.00
Forward P/E Ratio
19.80
P/E Growth
N/A
Net Income
$42.42 million
Pretax Margin
15.47%

Debt

Sales & Book Value

Annual Sales
$348.88 million
Cash Flow
$0.33 per share
Price / Cash Flow
17.93
Book Value
$1.31 per share
Price / Book
4.53

Miscellaneous

Free Float
145,191,000
Market Cap
$877.34 million
Optionable
Optionable
Beta
1.83
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:MDXG) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners